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Abstract
Background: Adverse drug reactions (ADRs) are a well-recognized public health problem and a major cause of
death and hospitalization in developed countries. The safety of a new drug cannot be established until it has been
on the market for several years. Keeping drug reactions under surveillance through pharmacovigilance systems is
indispensable. However, underreporting is a major issue that undermines the effectiveness of spontaneous reports.
Our work presents a systematic review on the use of information systems for the promotion of ADR reporting. The
aim of this work is to describe the state of the art information systems used to promote adverse drug reaction
reporting.
Methods: A systematic review was performed with quantitative analysis of studies describing or evaluating the use
of information systems to promote adverse drug reaction reporting. Studies with data related to the number of
ADRs reported before and after each intervention and the follow-up period were included in the quantitative
analysis.
Results: From a total of 3865 articles, 33 articles were included in the analysis; these articles described 29 different
projects. Most of the projects were on a regional scale (62 %) and were performed in a hospital context (52 %). A
total of 76 % performed passive promotion of ADR reporting and used web-based software (55 %). A total of 72 %
targeted healthcare professionals and 24 % were oriented to patient ADR reporting. We performed a meta-analysis
of 7 of the 29 projects to calculate the aggregated measure of the ADR reporting increase, which had an overall
measure of 2.1 (indicating that the interventions doubled the number of ADRs reported).
Conclusions: We found that most of the projects performed passive promotion of ADR reporting (i.e., facilitating
the process). They were developed in hospitals and were tailored to healthcare professionals. These interventions
doubled the number of ADR reports. We believe that it would be useful to develop systems to assist healthcare
professionals with completing ADR reporting within electronic health records because this approach seems to be
an efficient method to increase the ADR reporting rate. When this approach is not possible, it is essential to have a
tool that is easily accessible on the web to report ADRs. This tool can be promoted by sending emails or through
the inclusion of direct hyperlinks on healthcare professionals’ desktops.
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Background
Adverse drug reactions (ADRs) are a well-recognized
public health problem worldwide and a major cause
of death and hospitalization in developed countries
[1]. Rare and long-term ADRs are difficult to detect
during the drug development stage. Detecting new
ADRs not previously identified during clinical trials is
only possible when the drug begins to be used by a
large population after marketing authorization (MA).
The safety of a new drug cannot be established until
it has been on the market for several years [2]. As
such, it is indispensable to keep drug reactions under
close surveillance after commercialization through a
pharmacovigilance system to continuously evaluate
the drug’s safety profile. In most countries, the phar-
macovigilance system is based on spontaneous ADR
reports made by healthcare professionals and con-
sumers [3]. These reports can be made using paper,
telephone, e-mail or through an on-line form and
consist of a description of an adverse event appar-
ently caused by a medicine. Spontaneous ADR report-
ing has been described as an efficient method to
detect drug safety signs [4]; however, underreporting
is a major issue that undermines the effectiveness of
spontaneous reports. Several studies have suggested
that less than 10 % of detected ADRs are effectively
reported to medicine regulatory authorities [5, 6].
Worldwide, systems using informatics to promote
ADR reporting or to detect the occurrence of ADRs in
healthcare institutions have been tested and used, such
as computer programs that allow voluntary and auto-
mated detection of ADR [7, 8] informatics tools created
to analyse clinical databases [9] or websites that actively
inform healthcare professionals [10].
In addition to signal detection, information and com-
munication technologies can also be used to encourage
and facilitate reporting of suspected ADR.
In the present work, a systematic review is presented
on the use of information systems in pharmacovigilance.
Our main goal is to describe the state of the art informa-
tion systems for the passive or active promotion of ad-
verse drug reaction reporting.
Methods
Eligible studies
Studies describing or evaluating the use of information
systems to promote adverse drug reaction reports were
selected.
Review team
The review team is composed of two pharmacists who
are experts in pharmacovigilance (Inês Ribeiro Vaz (IV)
and Ana Marta Silva (AS)) and the computer scientist
Ricardo Cruz Correia (RC), who is an expert in medical
informatics.
Search methods
Studies were searched in April 2014 in the bibliographic
databases. We developed a search query that included
the concepts adverse drug reaction, adverse drug reac-
tion reporting system, pharmacovigilance and informa-
tion system. Only articles written in English, Portuguese
or French were included. We did not establish any
criteria for the publication date.
Four distinct bibliographic databases were searched:
Medline (via PubMed); ISI (ISI Web of Knowledge); IEEE
(IEEE Xplore) and Scopus. The query search string used in
Medline® was ((ADR OR “adverse drug reaction” OR
“adverse drug reactions” OR “adverse drug event” OR “ad-
verse drug events” OR “adverse dug effect” OR “adverse drug
effects”) OR “pharmacovigilance”). A similar query was used
in the other databases and was adapted to the search
engine.
Selection of studies for the review
The first selection was based on the study title and ab-
stract (when available). Two reviewers on the review
team (IV and AS) were involved in study selection and
read all titles/abstracts. The study was considered eli-
gible when at least one of the reviewers decided that the
title/abstract mentioned the key concept of using infor-
mation systems for ADR reporting. In cases of disagree-
ment, a consensus meeting was held with the third
reviewer (RC) to decide whether the article should be
selected.
The second phase of study selection was based on
the full text. The team leader (IV) reviewed each full-
text article. In this stage, articles were excluded based
on the following criteria: (1) the articles were only
focused on medication errors; (2) the articles focused
on ADR detection; (3) the articles were studies with-
out any information system implemented; (4) the arti-
cles were studies concerning data quality; (5) the
articles were studies focused on website usability; (6)
the articles were only the authors’ reflections on the
theme; (7) the articles were studies only related to
incidents that occurred in health institutions; (8) the
articles were studies concerning signal detection and
(9) the articles were studies concerning electronic
transmission between the authority and other institu-
tions (pharmaceutical companies or regional pharma-
covigilance centres).
The articles remaining after this review were included
in the final statistical analysis.
These articles were grouped into research projects to
avoid the distortion created by multiple papers describing
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the same project (Fig. 1). All statistical analyses were based
on the projects and not on the articles.
Definition of variables
The variables examined in these reviews were related to
the projects, papers and information systems described
in each project.
We used the following data for project identification:
(1) project number; (2) Information system name (if
any); (3) country; (4) publication date; (5) type of study
and (6) reference(s).
According to the description of the projects, the fol-
lowing variables were analysed:
1. Area covered by the project (i.e., region, country, or
hospital)
2. Type of action promoted by the project (passive
promotion of ADR reporting or active promotion of
ADR reporting)
3. Type of software (i.e., web-based or mobile)
4. Type of institution (i.e., regulatory authority or
universities)
5. Target (healthcare professionals or patients)
6. Type of medicine (all, vaccines, chemotherapy, or
others)
7. Type of ADR (all/serious ADRs based on the World
Health Organization seriousness criteria [11])
Statistical analysis
The inclusion criteria for the quantitative analysis were
the availability of data related to the number of ADRs
reported before and after each intervention and a
follow-up period.
Studies that only disclosed the increased ADR rate and
studies that reported zero ADRs before the project im-
plementation were excluded because it was not possible
to perform the analysis in these cases.
For each study with available data, the rate of ADRs
reporting increase (quotient between ADR reports
after and ADR reports before) and the respective
95 % confidence intervals were calculated. A rate of
ADR reporting increase equal to 2 indicated that the
ADR reports doubled after the intervention. Con-
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Fig. 1 Flowchart of the study selection
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indicated that the number of ADR reports after the
intervention was equal to the number of ADR reports
before the intervention. The aggregated rate of the
ADR reporting increase was calculated with the in-
verse variance method using a random effects model
and a forest plot was presented. The confidence inter-
vals, aggregated rate of ADRs and forest plot were
performed using a Microsoft Excel spreadsheet. The
description of the Microsoft Excel spreadsheet and
the respective statistical methods used were described
by Neyeloff [12].
Results
Our search method found 2519 articles in PubMed,
68 in IEEE, 2603 in ISI and 192 in Scopus. After
eliminating duplicate articles, 3835 articles were
selected.
Two reviewers (IV and AS) read all 3835 titles/ab-
stracts. In cases of disagreement, which occurred with
151 articles, a consensus meeting was held with the
third reviewer (RC) to decide whether the article
should be selected.
A total of 643 studies were excluded because they
were not related to pharmacovigilance, 85 were excluded
because they were not related to information systems
and 2993 were excluded for other reasons (mostly be-
cause their focus was on data mining in large databases
instead of ADR reporting).
A total of 114 of the 3835 articles were selected in this
first selection based on the title and abstract.
The team leader (IV) reviewed each of the 114 full-
text articles. After this review, 33 articles remained
for the final statistical analysis. At this stage, most of
the articles were excluded because: (1) they were only
related to medication errors; (2) they were focused on
ADR detection; (3) they were studies without any in-
formation system implemented; (4) they were studies
concerning data quality; (5) they were studies focused
on website usability; (6) they were only authors’ re-
flections on the theme; (7) they were studies only re-
lated to incidents that occurred at health institutions;
(8) they were studies concerning signal detection or
(9) they were studies concerning electronic transmis-
sion between the authority and other institutions
(pharmaceutical companies or regional pharmacovigi-
lance centres).
These 33 articles were grouped into 29 distinct re-
search projects to avoid the distortion created by
multiple papers describing the same project (Fig. 1.).
All statistical analyses was based on projects and not
on articles.
Table 1 lists all 29 projects, their country, the number
of publications, the publication year and the journal.
The country with the most published projects was the
USA (11), followed by the United Kingdom (3).
Trends
There was an increasing trend in publication, especially
after 2009 (Fig. 2).
Qualitative analysis
The qualitative variables analysed in each project are listed
in Table 2 and described below. Globally, we found that
there was an increase in the publication of projects over
the study period, with 4 projects published before 2001, 4
projects between 2005 and 2007, 8 projects between 2008
and 2010 and 13 projects between 2011 and 2013.
Geographic area covered by the projects
Most of the projects were regional (62 %), followed by
national projects (34 %). We found only 1 international
project based on Facebook®. This international project
was developed in the last time period (2011–2013).
Areas covered by the projects
Most of the projects (52 %) were developed in hospitals,
followed by community projects (21 %). A total of 14 %
covered primary care institutions and 10 % (3 projects)
were developed for use in any type of healthcare institu-
tion. One project was dedicated to a multicentre clinical
trial. We also found that all of the projects oriented to
the community were developed in the last 3 years
(2011–2013).
Types of actions promoted by the projects
The majority of the projects passively promoted ADR
reporting (76 %); the remainder actively promoted
reporting (24 %).
Types of software
More than half of the projects (55 %) used web-based
technology and 41 % used electronic health records.
Only one project used mobile phone technology. There
was an increasing trend in software using web-based
technology over all of the time intervals considered. The
mobile technology appeared during the last time period.
Types of institutions promoting the studies
Most of the projects were promoted by hospitals and
universities (31 % ex aequo). There were 4 projects de-
veloped by national institutions (not regulatory) and 5
projects implemented by regulatory authorities.
Targets
A total of 72 % of the projects were geared to healthcare
professionals, 24 % to patients and one project was
geared to both targets. Most of the projects targeting
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patient ADR reporting were developed in the last years
considered (2011–2013).
Types of medicine
Most of the projects (72 %) covered all medicines, but
17 % were specific to vaccines. There were also projects
specific to reporting ADRs due to chemotherapy, human
albumin and radiopaque agents (1 project for each of
these medicines).
Types of ADR
Only a small percentage of the projects were specific for
serious adverse drug reactions. The majority (93 %) cov-
ered all ADR.







Publication date(s) References Journals
4 USA 1 1992 [32] Hospital pharmacy
28 France 1 2001 [26] Fundamental & Clinical Pharmacology
11 Japan 1 2002 [33] Yakugaku Zasshi-Journal of the Pharmaceutical
Society of Japan
17 USA 1 2004 [34] American Journal of Health-System Pharmacy
2 USA 3 2005, 2007 [25, 35, 36] Journal of Clinical Oncology, Journal of American
Medical Information Association
22 USA 2 2005, 2006 [28, 37] Biosecurity and Bioterrorism-Biodefense Strategy
Practice and Science, Health Expectations
10 USA 1 2007 [29] Journal of the American Medical Informatics
Association
9 MEADERS USA 2 2007, 2010 [23, 38] Annals of Family Medicine, AMIA Annual
Symposium proceedings
21 Spain 1 2008 [39] Annals of Pharmacotherapy
7 Sweden 1 2009 [15] European Journal of Clinical Pharmacology
5 Canada 1 2010 [40] International Journal of Medical Informatics
13 Canada 1 2010 [27] Vaccine
18 USA 1 2010 [41] Pharmacoepidemiology and Drug Safety
19 United
Kingdom
1 2010 [42] Archives of Disease in Childhood
23 ALIAS USA 1 2010 [43] Contemporary Clinical Trials
27 Taiwan 1 2010 [14] Value in Health
8 United
Kingdom
1 2011 [44] Journal of Psychiatric and Mental Health Nursing
12 Serbia 1 2011 [20] Drug Safety
14 France 1 2011 [13] Therapie
15 USA 1 2011 [21] Paediatrics
6 United
Kingdom
1 2012 [45] Drug Safety
16 Korea 1 2012 [46] Yonsei Medical Journal.
20 Portugal 1 2012 [16] Drug Safety
25 USA 1 2012 [47] 2012 Ninth International Conference on Information
Technology: New Generations
1 Cambodge 1 2013 [22] Journal of Medical Internet Research
3 Netherlands 1 2013 [18] Studies in health technology and informatics
24 SALUS France 1 2013 [48] Studies in health technology and informatics
26 Spain 1 2013 [49] International Journal of Clinical Pharmacy
29 Denmark 1 2013 [17] European Journal of Hospital Pharmacy-Science
and Practice
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Quantitative analysis
From the 29 projects analysed, seven projects met the
criteria for inclusion in the quantitative analysis (meta-
analysis). The criteria used were the availability of data
related to the number of ADR reported before and after
each intervention and a follow-up period.
From the seven projects included in the quantitative
analysis, six had the same follow-up period (12 months)
and only one (project 14) differed on this item
(18 months of follow-up). The results are described in
Table 3.
We performed a meta-analysis with these seven projects
to calculate the aggregated measure of the ADR reporting
increase. The overall measure was 2.1, which indicated
that the interventions performed in the analysed projects
doubled the number of ADR reports (Fig. 3).
Projects 14, 7 and 6, which had similar ADR reporting
increases, used different approaches. The authors of pro-
ject 14 assessed an online ADR reporting form, in pro-
ject 7 the authors send repeated e-mails with ADR
information to healthcare professionals and project 6
evaluated the inclusion of a reporting system inside the
clinical information system.
Four of the information systems that contributed to the
improvement of ADR reporting used web-based technol-
ogy. Two used an online reporting form (Project 14 [13]
and Project 27 [14]) to facilitate ADR reporting. A Swed-
ish group opted to evaluate the effect of repeated emails
to health care professionals that contained attached ADR
information (Project 7 [15]). A Portuguese study tested
the inclusion of hyperlinks to the online ADR reporting
form on hospitals’ electronic patient records (Project 20
[16]) to facilitate access to the ADR form.
Three projects explored the use of electronic health
records to directly report the ADRs (projects 29, 6 and
17). Among these, project 29 [17], which had the best
result in terms of the ADR reporting increase, was a
system that completed the ADR report whenever a phys-
ician required assistance.
Discussion
Although a limited number of projects was included in
our work (n = 29), our data suggest that the number of
projects that aimed to promote ADR reporting using in-
formation technologies increased over time.
Study selection was performed as a manual review;
this approach caused a huge workload because we ob-
tained more than 3000 articles. An optimized query
would reduce the workload but lose sensitivity.
As expected, most of the projects that aimed to promote
adverse drug reactions reporting were developed in hospi-
tals and tailored to healthcare professionals. In fact, most
of the serious ADRs were detected in hospitals and re-
ported by healthcare professionals [18]. For example, in
Europe direct reporting (ADRs reported by patients) has
only been allowed for every country since 2012 [19]. This
finding may also explain why most of the projects that tar-
geted direct ADR reporting were developed in the last 3
years of the study period (2011–2013) [18, 20–22].
Most of the authors chose to develop systems for the
passive promotion of ADR reporting because busy
healthcare professionals only submit their suspected
ADR if it does not increase their workload [23, 24]. Ac-
tive promotion of ADR reporting is difficult and not al-
ways ethically acceptable because no material reward
can be given to the reporters. Thus, projects that aimed
to actively promote ADR reporting involved teaching
sessions [25] or e-mails containing ADR information
[15, 18, 26, 27].
Our results suggested that there was an increasing
trend in the use of web-based software to promote
ADR reporting, which could be explained by the
Fig. 2 Number of publications by year
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Table 2 Qualitative analysis of the projects











Geographic area covered by the
project
Regional 4 3 5 6 18 (62) 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17,
20, 21, 22, 26, 27, 28, 29
National 0 1 3 6 10 (34) 1, 3, 6, 9, 15, 18, 19, 23, 24, 25
International 0 0 0 1 1 (3) 12
Area covered by the project
Hospital 4 2 5 4 15 (52) 2, 4, 5, 8, 11, 13, 17, 18, 20, 21, 22,
26, 27, 28, 29
Community 0 0 0 6 6 (21) 1, 3, 12, 14, 15, 16
Primary care 0 2 1 1 4 (14) 6, 7, 9, 10
Other healthcare institutions
(different from hospitals or primary
care)
0 0 1 2 3 (10) 19, 24, 25
Clinical trials 0 0 1 0 1 (3) 23
Type of action promoted by the
project
Passive promotion of ADR reporting 3 3 6 10 22 (76) 4, 5, 6, 8, 9, 10, 11, 14, 15, 16, 17, 18,
19, 20, 21, 22, 23, 24, 25, 26, 27, 29
Active promotion of ADR reporting 1 1 2 3 7 (24) 1, 2, 3, 7, 12, 13, 28
Type of software
Web-based 1 3 6 6 16 (55) 2, 3, 5, 7, 9, 12, 13, 14, 15, 16, 19, 20,
22, 23, 27, 28
System inside the Electronic Health
Record
3 1 2 6 12 (41) 4, 6, 8, 10, 11, 17, 21, 24, 25, 26, 18, 29
Mobile 0 0 0 1 1 (3) 1
Type of institution promoting the
study
Hospital 2 1 3 3 9 (31) 2, 4, 8, 17, 18, 21, 26, 27, 29
University 1 1 3 4 9 (31) 5, 10, 11, 12, 13, 19, 20, 24, 25
National institution 0 2 0 2 4 (14) 1, 9, 15, 22
Regulatory authority 1 0 1 3 5 (17) 6, 7, 14, 16, 28
Othera 0 0 1 1 2 (7) 3, 23
Target
Healthcare professionals 4 2 7 8 21 (72) 4, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 18,
19, 21, 23, 24, 25, 26, 27, 28, 29.
Patients 0 2 1 4 7 (24) 1, 2, 3, 5, 12, 20, 22
Healthcare professionals and
patients
0 0 0 1 1 (3) 15
Type of medicine
All 4 1 5 11 21 (72) 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 16, 17, 18,
19, 20, 21, 24, 25, 26, 28, 29
Vaccines 0 2 1 2 5 (17) 1, 10, 13, 15, 22
Chemotherapy 0 1 0 0 1 (3) 2
Human albumin 0 0 1 0 1 (3) 23
Radiopaque agents 0 0 1 0 1 (3) 27
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dissemination of internet use. Nevertheless, mobile
technology was also appearing.
Most of the retrieved projects covered all medicines and
ADR, whereas only a few were specific. However, we
found 5 projects dedicated to vaccine adverse reactions
[21, 22, 27–29] and in the last 3 years two projects were
developed to specifically report serious ADR [18, 22].
The institutions that primarily promoted this work
were universities and hospitals because universities have
the know-how to perform these actions and hospitals
have specific needs to be solved. However, regulatory au-
thorities have been increasing their involvement in the
development of this type of project.
A limitation of this study is that a grey literature
search was not performed. However, we think that
this lack does not cause a large bias because regula-
tory authorities are less likely to produce this type of
project. When regulatory authorities are involved in
projects of this scope, they usually associate with uni-
versities and hospitals that have a greater incentive to
publish.
Based on our quantitative analysis, we can conclude
that all of the projects analysed increased the ADR
reporting numbers (most by approximately two-fold).
We found two projects that increased ADR reporting by
more than two-fold [14, 17], perhaps because their basal
values were much lower compared with the other five
projects. A similar effect was noted previously in two
other studies when the same population of health care
professionals was exposed to the same educational inter-
ventions two different times [30, 31]. After the first
intervention, the authors achieved a much higher effect
and ADR reporting increased compared to the second
intervention due to the differences in the initial values.
In our quantitative analysis, we found a limitation con-
cerning the aggregation of the information because we
found only 7 studies that provided data concerning its im-
pact on the increase in ADR reporting. These data were
not available for the other studies even after we contacted
the authors. However, we did not identify any variable that
could distinguish these 7 projects from the other 22 pro-
jects. We must reiterate the importance of providing
quantitative data when publishing studies focused on in-
terventions that aim to promote ADR reporting.
Worldwide underreporting of ADR is a major concern,
and many institutions are aware that it is feasible to use
information systems to improve ADR reporting. The
most commonly used platform is web-based and exhibits
an increasing trend, but interventions inside electronic
health records also have the potential to improve phar-
macovigilance activities and particularly ADR reporting.
Direct ADR reporting is being increasingly taken into
account when the aim is to improve information on
drug safety.
Based on our results, we believe that it would be use-
ful to adopt a system to assist healthcare professionals
with completing ADR reporting within electronic health
records because this approach seems to be an efficient
method to increase the ADR reporting rate. When this
approach is not possible, it is essential to have a tool that
is easily accessible on the web to report ADR. This tool
can be promoted by sending emails or through the in-
clusion of direct hyperlinks on healthcare professionals’
desktops.
Table 2 Qualitative analysis of the projects (Continued)
Type of ADR
All 4 4 8 11 27 (93) 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
Serious 0 0 0 2 2 (7) 1, 3
a Other institutions are: Clinical trial team (project 23) and website producer (project 3)
Table 3 Intervention effect on ADR reporting increase
Study ADR reports before ADR reports after Rate CI lower CI upper
Project 14 287 415 1,44 −0,18 3,07
Project 7 89 111 1,25 −0,51 3,00
Project 29 30 162 5,4 4,56 6,24
Project 6 3279 4716 1,44 −0,20 3,072
Project 17 118 294 2,49 1,25 3,73
Project 27 20 62 3,1 1,99 4,21
Project 20 82 212 2,58 1,37 3,80
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Conclusions
Our systematic review allowed us to note some facts
about interventions that aim to improve ADR reporting
using information systems. According to our aggregation
analysis, these interventions doubled the number of
ADR reports. We also found that most projects passively
promoted ADR reporting (facilitating the reporting
process) and the countries involved in this type of pro-
ject were Northern America countries (USA and
Canada), European countries and in a smaller number
Far East countries.
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